ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. Its pipeline also includes antinen for triple negative androgen receptor (AR+) breast cancer. Its proprietary aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting ARdriven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.